AUTHORS
Pankit Vachhani, MD, Tania Jain, MBBS2, Francesco Passamonti, MD3, Aaron T. Gerds, MD, MS4, Alessandro Lucchesi, MD, PhD5, Giulia Benevolo, MD6, Alessandro Maria Vannucchi7, Francoise Boyer8, Prithviraj Bose, MD9, Florian Heidel10, Zhuying Huang11, Hope Qamoos, NP12, Jesse McGreivy13, Wayne Rothbaum, MS14, Srdan Verstovsek, MD15, John O. Mascarenhas, MD16
AFFILIATIONS
1 Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama, United States
2 Johns Hopkins Medicine, Baltimore, Maryland, United States
3 Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy, Italy & Foundation IRCCS Ca’ Granda Maggiore Policlinico Hospital, Milan, Italy
4 Cleveland Clinic Foundation, Cleveland, Ohio, United States
5 Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
6 Division of Haematology, Turin City of Health and Science Hospital, Turin, Italy
7 Center for Research and Innovation of Myeloproliferative Neoplasms (CRIMM) University of Florence, Florence, Italy
8 University Hospital d'Angers, Angers, France
9 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 Hannover Medical School, Hannover, Germany
11 Kartos Therapeutics Inc., Redwood City, California, United States
12 Kartos Therapeutics Inc., Redwood City, California, United States
13 Kartos Therapeutics Inc., Redwood City, California, United States
14 Kartos Therapeutics Inc., Redwood City, California, United States
15 Kartos Therapeutics Inc., Redwood City, California, United States
16 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
ABSTRACT
Introduction: The JAK inhibitor (JAKi) ruxolitinib (RUX) is the standard-of-care first-line therapy for patients (pts) with myelofibrosis (MF). However, most pts experience suboptimal response or disease progression, ultimately requiring additional therapy. While switching to an alternative JAKi may modestly improve spleen and symptom responses, currently available JAKi therapies have demonstrated limited evidence of disease-modifying activity. Consequently, there remains a substantial unmet need for therapeutic strategies that improve clinical outcomes and target the underlying biology of MF.
Navtemadlin (NVTM) is an investigational mouse double minute 2 (MDM2) inhibitor that restores p53-mediated apoptosis in malignant CD34+ MF progenitor cells. NVTM has demonstrated clinically meaningful reductions in spleen volume and symptom burden, manageable safety, and disease-modifying potential in pts with MF. In the Phase 1b/2 KRT-232-109 study, add-on NVTM in pts with suboptimal response to RUX resulted in clinically meaningful improvements in spleen volume reduction (SVR) and total symptom score (TSS) with improvements in biomarkers of disease modification (Mascarenhas 2023).
In the absence of head-to-head studies, a matching-adjusted indirect comparison (MAIC) was conducted to estimate the comparative efficacy of add-on NVTM to ongoing RUX using data from the KRT-232-109 study versus switching to momelotinib (MMB) using data from the Phase 3 SIMPLIFY 2 study (Harrison 2018). SIMPLIFY 2 largely enrolled pts with inadequate response and/or intolerance to RUX, including those requiring dose reduction because of hematologic toxicity. Consequently, both the KRT-232-109 and SIMPLIFY 2 studies evaluated clinically overlapping populations with insufficient benefit from RUX.
Methods: Individual data were obtained from pts who received NVTM at the 240 mg dose (N=27) in the KRT-232-109 trial (NCT04485260), which enrolled adults with primary or secondary MF and a suboptimal response to RUX after ≥18 weeks. Pts received oral NVTM 240 mg on Days 1–7 of each 28-day cycle added to ongoing RUX. The primary endpoint was SVR ≥35% (SVR35) by MRI/CT at Week 24 (Wk24), and a key secondary endpoint was TSS reduction ≥50% (TSS50) at Wk24.
Published aggregate pt data were obtained from the Phase 3 SIMPLIFY 2 trial (NCT02101268). SIMPLIFY 2 enrolled adults with primary or secondary MF who had suboptimal response or hematologic toxic effects with RUX after ≥4 weeks. Pts were randomized to treatment with MMB (n=104) or best available therapy (BAT; n=52). For the MAIC analysis, individual pt data for NVTM + RUX (KRT-232-109) were weighted to match baseline characteristics of MMB-treated pts reported in SIMPLIFY 2, including spleen volume, TSS, prior RUX exposure, Dynamic International Prognostic Scoring System (DIPSS) risk score, hemoglobin level, and platelet count. Comparative analyses of SVR35 and TSS50 at Wk24 were subsequently performed. As no common comparator was available across studies, the MAIC was unanchored.
Results: After weighting and matching, mean baseline values were comparable across treatment groups for spleen volume [2511–2512 cm3], TSS [18.4–18.5], hemoglobin [9.4 g/dL], and platelet count [171 × 109/L]. Distribution of DIPSS risk categories (intermediate-1 [22.1–22.9%], intermediate-2 [59.2–59.6%]; high [17.9–18.3%]), was also similar. Prior RUX exposure ≥12 weeks remained higher in the NVTM cohort (100%) than in the MMB (72%) cohort. The effective sample size for the NVTM cohort was 14.17.
In the MAIC analysis, SVR35 at Wk24 was achieved in 32% of pts for NVTM + RUX versus 7% for MMB while TSS50 was achieved in 34% versus 26%, respectively. For context, published Wk24 outcomes for the BAT arm of SIMPLIFY 2 were SVR35 of 6% and TSS50 of 6%.
Conclusions: In this unanchored MAIC, add-on NVTM plus ongoing RUX was associated with higher rates of SVR35 and TSS50 at Wk24 compared with switching to MMB in patients with MF previously treated with RUX. These findings highlight the potential utility of add-on NVTM for pts with prior RUX treatment and further support clinical development of NVTM in MF. The ongoing Phase 3, placebo-controlled POIESIS trial (NCT06479135) is evaluating NVTM as add-on therapy to RUX in pts with MF who have a suboptimal response to first-line RUX.
DISCLOSURES
Pankit Vachhani, MD: Novartis - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Blueprint Medicines Corporation, a wholly owned subsidiary of Sanofi - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Kartos - Consultancy (Includes expert testimony); Silence Therapeutics - Consultancy (Includes expert testimony); Prelude Therapeutics - Consultancy (Includes expert testimony); DISC Medicine - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Merck & Co., Inc - Consultancy (Includes expert testimony)